NeOnc CEO Amir Heshmatpour’s 2026 Open-Market Share Purchases Exceed $1.5 Million
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeOnc Technologies Holdings (Nasdaq: NTHI) announced that CEO Amir F. Heshmatpour purchased 30,000 shares on the open market on November 13, 2026.
His 2026 open-market purchases total 371,000 shares for more than $1.5 million, including 180,000 shares in November. He used personal funds; NeOnc issued no shares. Since the August 12, 2026, topline Phase 2a results for intranasal NEO100, he has purchased 291,000 shares for more than $1 million. NeOnc has an FDA Type B End-of-Phase meeting scheduled for early January 2027 to seek feedback on a potential accelerated approval pathway and a proposed Phase 3 confirmatory trial.
Positive
- Minor pointCEO’s personally funded open-market purchases reached 371,000 shares for more than $1.5 million in 2026, without new shares issued.
- Minor point. Forward-looking: it has not happened yet and may not happen.FDA meeting scheduled for early January 2027 to seek feedback on potential accelerated approval and proposed confirmatory trial design.
Negative
- None.
Key Figures
- Latest open-market purchase
- 30,000 shares
- Purchased November 13, 2026
- 2026 open-market purchases
- 371,000 shares
- Year-to-date total
- 2026 purchase value
- More than $1.5 million
- Year-to-date open-market purchases
- November purchases
- 180,000 shares
- Included in the 2026 total
Historical Context
-
CEO reported another 70,000-share purchase as the company prepared for January FDA discussions.
-
CEO disclosed 80,000 open-market shares purchased across three November trading dates.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
type b end-of-phase meeting regulatory
accelerated approval pathway regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Latest purchase of 30,000 shares brings year-to-date total to 371,000 shares
CALABASAS, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) today announced that Amir F. Heshmatpour, its Executive Chairman, President and Chief Executive Officer, purchased 30,000 shares of NeOnc common stock on the open market on November 13, 2026. The transaction brings his 2026 open-market purchases to 371,000 shares for more than
Since NeOnc reported topline Phase 2a results for intranasal NEO100 on August 12, 2026, Mr. Heshmatpour has purchased 291,000 shares for more than
“I’ve continued to buy NeOnc shares with my own funds because I believe in the work our team is doing for patients with brain cancer,” said Mr. Heshmatpour. “That conviction has only grown after spending time with children receiving investigational NEO100 through our compassionate care program at Burjeel Medical City in Abu Dhabi. What I’ve witnessed firsthand there has stayed with me. As I’ve said before, I believe God’s hand is in this work.”
NeOnc has a Type B End-of-Phase meeting scheduled with the U.S. Food and Drug Administration (FDA) in early January 2027 to seek feedback on a potential accelerated approval pathway for investigational intranasal NEO100 and the design of a proposed Phase 3 confirmatory trial.
About NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers. Its investigational programs include intranasal NEO100 and oral NEO212. NEO212 has completed Phase 1 dose escalation and is advancing toward Phase 2 development. NeOnc exclusively licenses a worldwide portfolio of issued patents and pending applications from the University of Southern California related to NEO100, NEO212 and other drug candidates and delivery approaches. For more information, visit https://neonc.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the anticipated timing of the FDA meeting, the topics to be discussed, a potential accelerated approval pathway, the proposed NEO100 Phase 3 trial, the Company’s clinical development programs, and the clinical potential of NEO100 and NEO212. These statements reflect current expectations and involve risks and uncertainties. NEO100 is investigational and has not been approved by any regulatory authority; future studies may not demonstrate safety or efficacy; results from compassionate use involving individual patients may not be predictive of results in clinical trials; clinical development remains subject to applicable clinical, regulatory and institutional requirements; and no regulatory pathway or marketing approval is assured. The scheduling of the FDA meeting does not establish FDA agreement on a development plan, an accelerated approval pathway or eventual approval of NEO100. NEO212 is also investigational and has not been approved by any regulatory authority. The NEO100 Phase 2a study was a single-arm, open-label study that was not powered as a confirmatory trial. The Company will require substantial additional capital to fund its operations, which may not be available on acceptable terms or at all. Actual results may differ materially. Readers should consider the risk factors described in the Company’s most recent filings with the Securities and Exchange Commission. These statements speak only as of the date of this release. The Company undertakes no obligation to update forward-looking statements except as required by law.
“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Contacts
Company Contact:
info@neonc.com
Investor Contact:
Jon Nugent
Jon Nugent Communications
jon@jonnugent.com
205-566-3026
This press release was published by a CLEAR® Verified individual.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much NeOnc stock has CEO Amir Heshmatpour bought in 2026?
Heshmatpour’s 2026 open-market purchases total 371,000 shares for more than $1.5 million, including 180,000 shares in November. His latest purchase was 30,000 shares on November 13, 2026. He used personal funds, and NeOnc issued no shares in connection with the purchases.